

**NATIONAL CANCER INSTITUTE-FREDERICK (NCI-F)**  
**INSTITUTIONAL BIOSAFETY COMMITTEE**  
**MINUTES**  
**SEPTEMBER 17, 2013**

**CALL TO ORDER / ANNOUNCEMENTS**

The NCI-F Institutional Biosafety Committee was convened at 12:04 pm in Building 549 Executive Board Room with the following members in attendance:

Voting (Quorum = 8)

- Katalin Baranji
- Michael Baseler (regrets)
- Theresa Bell
- Rev. David Betzner
- Stephen Creekmore
- Bruce Crise
- Eric Freed
- Melinda Hollingshead

- Stephen Hughes
- Sarah Hooper
- Serguei Kozlov (regrets)
- Dan McVicar (Chair) (regrets)
- Randall Morin
- Raja Sriperumbudur
- Lucien Winegar
- Enrique Zudaire

Non-Voting

- Walter Hubert
- Kim DiGiandomenico
- Karen Barber

Other

Two summer interns from Occupational Health

**APPROVAL OF MINUTES FROM JULY 16, 2013 MEETING**

The minutes from the August 20, 2013 meeting were approved as written. A motion and second were made (For: 14; Against: 0; Abstain: 0)

**ACCIDENT REVIEWS - None**

**REVIEW OF PROTOCOLS**

***NEW REGISTRATIONS***

Joel Schneider – 17-75 (New): Distribution and activity of anticancer peptides and peptide-drug conjugates in a cancer mouse model. This registry uses a CFH and has a clear SOP and experienced staff. Melinda Hollingshead moved to approve the registry. Raja Sriperumbudur seconded the motion. For: 12; Against: 0; Abstain: 0

Joel Schneider – 13-77 (New): Correlation of Tumor Mechanical rigidity to cancer grade and stage using a tumor-bearing mouse model. This registry was approved pending clarifications – need strain sheet and clarify NIH classification number. Randall Morin motioned to approve the registry. Melinda Hollingshead seconded the motion. For: 12; Against: 0; Abstain: 0

**NATIONAL CANCER INSTITUTE-FREDERICK (NCI-F)**  
**INSTITUTIONAL BIOSAFETY COMMITTEE**  
**MINUTES**  
**SEPTEMBER 17, 2013**

Matthew Young – 13-78 (New): Determination of toxicity, pharmacokinetics, scheduling and therapeutic potential of compounds and biologicals developed at the NCI. Approval will be deferred based upon the recommendation that an IBC be submitted at the time they have a biologically hazardous material with which to work. Given that the registry submitted indicates there are no details as to what may be researched at this time, there is nothing to issue an approval for. At the time the ASP would be submitted for this work, the IBC could be submitted simultaneously. **No approval**

Wang-Ting Hsieh – 13-79 (breeding only) – Generation of Speed Congenic Mouse Strains. Need clarification that the mice are not being made with any retroviral constructs. Current approval is pending receipt of information that there are no mobilizable elements used. He needs to assure us what the constructs are that will be used and how they are made. If there are mobilizable elements within the constructs, we will require descriptions of such and will defer this back to committee to review and approve. Bruce Crise moved to approve the registry pending clarifications. Randall Morin seconded the motion. For: 12; Against: 0; Abstain: 0

George Pavlakis – 13-80 (New): Use of lymphodepletion and adoptive cell transfer in the evaluation of cancer vaccine in mouse models. Theresa Bell deferred based on lack of information and no ASP. Randall Morin seconded the motion. . For: 12; Against: 0; Abstain: 0

**RENEWALS**

Nadya Tarasova – 13-76 (P100292CMA01): Established cancer cell lines will be cultured and used for studying the effects of newly synthesized agents on a cell growth. Remove language from the SOP that is not relevant to this IBC registry. Eric Freed moved to approve the registry. Melinda Hollingshead seconded the motion. For: 12; Against: 0; Abstain: 0

Scott McNeil – 13-81 (10-49): Determination of Nanoparticle Disposition and Acute Toxicity (this project uses the SXR2 KO mice). Needs a SOP for work with lymph node biopsies returned to the ATRF location. All other procedures conducted within LASP facilities with LASP approved SOP's. Approved pending leads reviewing SOP once submitted. Radiation program was confirmed and documented within the application. Melinda Hollingshead approved pending clarifications. Raja Sripurumbudur seconded the motion. For: 12; Against: 0; Abstain: 0

**OUTSTANDING ITEMS**

Lino Tessarollo 13-66 (10-38): Gene expression in mouse primary and established cell lines using Lentiviral and Adenoviral systems. This lab focuses on the analysis of murine models relevant to the study of the function of Neurotrophins and their receptors *in vivo*. The protocol includes cloning through standard molecular biology techniques into retroviral vectors that are then used to transduce cells and induce, or block, specific gene expression to study downstream events. Additionally, the lab will use Cre-expressing Adenovirus to transduce cells to study downstream signaling events. The committee requested additional clarification for the hazards of proteins being manipulated, as statements in Part B were contradictory, and also requested a post-approval lab visit to evaluate how materials are being manipulated. Awaiting response from PI. For: 12; Against: 0; Abstain: 0

Chuck Ostermeier 13-70 (10-36): Cryopreservation and assisted reproduction of genetically important mice and rats. As a service provided to investigators, this lab will collect and freeze sperm, embryos, and/or ovaries from transgenic, knockout or mutant strains of mice and/or rats. Upon request, pups will be reconstituted from the frozen state and delivered to the investigator. Additionally, assisted reproductive technologies will be utilized to rapidly generate colonies for investigation and to re-derive

**NATIONAL CANCER INSTITUTE-FREDERICK (NCI-F)**  
**INSTITUTIONAL BIOSAFETY COMMITTEE**  
**MINUTES**  
**SEPTEMBER 17, 2013**

animals from a contaminated or unknown health status to a specific pathogen free status. The committee expressed concerns with some of the information provided in Section E regarding the 'uncertainties' of some of the materials being received. They requested for the PI to develop a request form, similar to that used in the Transgenic Mouse Core, to assist with determining the hazards involved with the materials being received. Then the registry can refer to the request form. **Committee continues to wait for response from PI.** For: 12; Against: 0; Abstain: 0

Bill Kopp 11-28-A2: Add Vaccinia samples (saliva and urine as well as swabs taken from the vaccination site or from pustules distal (>5cm) from the vaccination site). Theresa Bell presented. Coulter Counter to be placed in containment when in use for studies with vaccinia within Room 121B. Theresa Bell motioned to approve this registry. Steve Hughes seconded the motion. For: 12; Against: 0; Abstain: 0

Dimitar Dimitrov 13-38 (04-04, 08-20): Developing anti-viral vaccines and human antibodies against infectious diseases and cancer antigens by using recombinant membrane proteins of HIV, Nipah, Hendra, Dengue viruses and cancer antigens Committee requested additional clarifications and a Vaccinia-specific SOP as well as a lab visit. Post-meeting, Theresa Bell learned that the lab was relocating and suggested that the space that will be used for the Vaccinia work should not be evaluated until the move has been completed. **Deferred until lab move and observation are completed.** For: 12; Against: 0; Abstain: 0

John Gilly 13-45 (10-16): Use of HEK 293 Cells for Alphavirus Vaccine Production Containment and photos submitted are acceptable. Approved renewal for work with cells. All other processes to be approved under future amendments. Steve Hughes motioned to approve. Bruce Crise seconded the motion. For: 12; Against: 0; Abstain: 0

#### **AMENDMENTS**

Ten amendments were processed and approved between the July and August IBC meetings.

#### **OTHER BUSINESS**

- Melinda Hollingshead - Committee discussion regarding primary human tissue when passaged more than once and if biosafety levels can be modified based on reduced risk.

#### **ADJOURNMENT**

The meeting adjourned at 1:45pm.

***Next meetings:***

***October 15,, 2013***

***November 19,, 2013***